Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ultragenyx Pharmaceutical's earnings before interest and taxes (EBIT) for the
three
months ended in Mar. 2026 was $-163.0 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-536.6 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Ultragenyx Pharmaceutical's annualizedROC % for the quarter that ended in Mar. 2026 was -89.24%.
Ultragenyx Pharmaceutical's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -269.98%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Ultragenyx Pharmaceutical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -27.84%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ultragenyx Pharmaceutical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ultragenyx Pharmaceutical EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Ultragenyx Pharmaceutical's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-536.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ultragenyx Pharmaceutical (LTS:0LIF) has a EBIT of $-536.6 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ultragenyx Pharmaceutical.
Is Ultragenyx Pharmaceutical's EBIT too high?
Ultragenyx Pharmaceutical's current EBIT is $-536.6 Mil. Overall, Ultragenyx Pharmaceutical has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ultragenyx Pharmaceutical's EBIT compare to ATAI and QURE?
Ultragenyx Pharmaceutical's EBIT of $-536.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's current EBIT is $-536.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ultragenyx Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Ultragenyx Pharmaceutical (LTS:0LIF) is currently considered Possible Value Trap. The stock's GF Value™ is $46.14, compared to a current price of $25.26 — trading 45.3% below its estimated fair value. The current EBIT is $-536.6 Mil. Ultragenyx Pharmaceutical's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Ultragenyx Pharmaceutical (LTS:0LIF), the current EBIT is $-536.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ultragenyx Pharmaceutical (LTS:0LIF) Overvalued in 2026?
Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued.
The current stock price of $25.26 is trading 45.3% below its estimated GF Value™ of $46.14.
GuruFocus considers Ultragenyx Pharmaceutical to be Possible Value Trap.
Key valuation signals for LTS:0LIF:
EBIT: $-536.6 Mil
GF Value™: $46.14 vs. price of $25.26 (45.3% below fair value)
No single metric tells the full story. See the LTS:0LIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
65GF Score
Get the complete analysis for LTS:0LIF
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0LIF has been successfully added to your 
